

CORRECTION

Open Access



Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Wenxing Chen^{1,2}, Yanhong Pan¹, Siliang Wang¹, Yuping Liu¹, Guangying Chen³, Liang Zhou¹, Chao Zhang⁴, Wenting Ni¹, Aiyun Wang¹, Yin Lu^{1,2*} and Shile Huang^{4*}

Correction to: *BMC Cancer* (2017) 17:34
<https://doi.org/10.1186/s12885-016-3038-y>

Following publication of the original article [1], the author noticed the following errors in the article.

1) The following authors were mistakenly omitted from the published article:

- a. Dr. Shile Huang as lead corresponding author
- b. Dr. Chao Zhang as co-author

The correct authorship is as follows:

Wenxing Chen^{1,2}, Yanhong Pan¹, Siliang Wang¹, Yuping Liu¹, Guangying Chen³, Liang Zhou¹, **Chao Zhang⁴**, Wenting Ni¹, Aiyun Wang¹, **Yin Lu^{1,2*}** and **Shile Huang^{4*}**.

* Correspondence: shuan1@lsuhsc.edu and luyingreen@126.com

2) Correction to Acknowledgement statement. The correct statement is as follows:


This work was supported in part by Natural Science Foundation of Jiangsu Province (BK2012854, W. Chen), National Natural Science Foundation of China (81673648, W. Chen; 81173174, Y. Lu; 21162009, G. Chen), the National Institutes of Health NCI CA115414, S. Huang), American Cancer Society (RSG-08-135-01-CNE, S. Huang), Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, and a project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Qing Lan Project of Jiangsu and a preliminary foundation of NJUCM (13XYYZ4).

3) Correction to Authors' contribution statement. The correct statement is as follows:

WXC, YL, and SH conceived the project and designed the research. WXC performed adenoviral and lentiviral assays, and YHP, YPL, WTN, and CZ conducted cell culture and western blot. SLW conducted the molecular docking. LZ prepared the figures and performed the statistical analysis. AYW, GYC, and YL participated in coordination. WXC wrote the manuscript. All authors read and approved the final manuscript.

4) Figure correction: The authors noticed an error in Fig. 8a. Please see the correct Fig. 8a and figure legend below.

The authors apologize for any inconvenience caused.



* Correspondence: luyingreen@126.com; shuan1@lsuhsc.edu

¹School of Pharmacy, Nanjing University of Chinese Medicine, NO.138, Xianlin Avenue, Nanjing 210023, Jiangsu Province, China

⁴Louisiana State University Health Sciences Center, Shreveport, LA, USA

Full list of author information is available at the end of the article



Author details

¹School of Pharmacy, Nanjing University of Chinese Medicine, NO.138, Xianlin Avenue, Nanjing 210023, Jiangsu Province, China. ²Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China. ³College of Chemistry and Chemical Engineering, Hainan Normal University, Haikou 571158, China. ⁴Louisiana State University Health Sciences Center, Shreveport, LA, USA.

Received: 12 March 2019 Accepted: 12 March 2019

Published online: 21 March 2019

Reference

1. Chen W, et al. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells. *BMC Cancer*. 2017;17:34. <https://doi.org/10.1186/s12885-016-3038-y>.